Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Fengyuan Mandy Yang"'
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Activated effector T cells (Teff) and/or compromised regulatory T cells (Treg) underlie many chronic inflammatory diseases. We discovered a novel pathway to regulate survival and expansion of Teff without compromising Treg survival and a potential th
Externí odkaz:
https://doaj.org/article/a9382a08ebc54445a555b35c5f0f9710
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Innate anti-inflammatory mechanisms are essential for immune homeostasis and can present opportunities to intervene inflammatory diseases. In this report, we found that YAP isoform 9 (YAP9) is an essential negative regulator of the potent inflammator
Externí odkaz:
https://doaj.org/article/48f7e41a702047eaa1e97b59273bb716
Autor:
Jongdae Lee, Beatriz Lozano-Ruiz, Fengyuan Mandy Yang, Dengxia Denise Fan, Liya Shen, Jose M. González-Navajas
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
During the last decade, immune checkpoint inhibition (ICI) has become a pillar of cancer therapy. Antibodies targeting CTLA-4 or PD-1/PD-L1 have been approved in several malignancies, with thousands of clinical trials currently underway. While the ma
Externí odkaz:
https://doaj.org/article/e990e46366cf4d8b8f73790fee639c6f
Autor:
Jose M. González-Navajas, Dengxia Denise Fan, Shuang Yang, Fengyuan Mandy Yang, Beatriz Lozano-Ruiz, Liya Shen, Jongdae Lee
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Although cancers arise from genetic mutations enabling cells to proliferate uncontrollably, they cannot thrive without failure of the anticancer immunity due in a large part to the tumor environment's influence on effector and regulatory T cells. The
Externí odkaz:
https://doaj.org/article/3d3d6fd74f6347d088b8c82513aa9a9b
Autor:
Jongdae Lee, Beatriz Lozano-Ruiz, Fengyuan Mandy Yang, Dengxia Denise Fan, Liya Shen, Jose M. González-Navajas
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
During the last decade, immune checkpoint inhibition (ICI) has become a pillar of cancer therapy. Antibodies targeting CTLA-4 or PD-1/PD-L1 have been approved in several malignancies, with thousands of clinical trials currently underway. While the ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fb0e4896b9103b5da5c7d105d0e39b8
https://pubmed.ncbi.nlm.nih.gov/33777008
https://pubmed.ncbi.nlm.nih.gov/33777008